Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

Tim Mok, PharmD, BCPS, BCOP, malignant hematology pharmacy research analyst at Kaiser Permanente, discussed his perspective on the balance between clinical outcomes and cost considerations. 

Dr Tim Mok: A Pharmacist's Perspective on Balancing Costs and Outcomes

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

Videos

Tiago Biachi, MD, PhD, discusses the challenges of treating gastrointestinal (GI) cancers, particularly the limited effectiveness of immunotherapy for "cold tumors" and the need to make them more responsive to immune treatments.

Empowering Patients With GI Cancer: Overcoming Immunotherapy Limitations

Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.

He has an MA from University of Sioux Falls. You can connect with Jared on 

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed. 

Efgartigimod Leads to Sustained Myasthenia Gravis Improvement

A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension (PAH). 

High Uric Acid Appears to Have Causal Role in PAH

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

CHEST 2024 Key Takeaways: Innovations in IPF and PAH 

Implications of IPF Survival Data for Clinical Practice and Early Intervention

What are your key takeaways from this study, and how has the data enhanced our understanding of the relationship between early diagnosis and prognosis in patients with IPF?

Steven Nathan, MD, discusses how key findings from CHEST 2024, including survival predictors from the IPF-PRO Registry and the potential of inhaled treprostinil for CTD-PAH, are shaping new approaches to managing IPF and PAH, with a focus on early diagnosis, personalized treatments, and improving patient outcomes.

Coming into CHEST 2024, Steven Nathan, MD, discusses how the largest unmet needs in the treatment and management of IPF and PAH include improving early diagnosis, addressing symptom management (particularly chronic cough), and developing more effective, accessible therapies to enhance long-term patient outcomes.

CHEST 2024: Updates in IPF and PAH Care

Steven Nathan, MD, discusses the abstract “Predicting Long-Term Survival in Patients With Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry,” which aimed to identify key predictors of long-term survival in IPF using data from the IPF-PRO Registry; the study employed a classification and regression tree model to analyze variables such as FVC percent predicted, oxygen use, BMI, and age, and found that factors such as oxygen use and FVC levels were strong predictors of survival beyond 5 years.

Key Predictors of Survival in IPF: Findings From the IPF-PRO Registry

Steven Nathan, MD, discusses how the data from the IPF-PRO Registry highlights the critical relationship between early diagnosis and prognosis in IPF, revealing that FVC percent predicted, oxygen use, BMI, and age are key indicators of long-term survival, underscoring the importance of early identification, and personalized treatment plans to improve patient outcomes.

Steven Nathan, MD, discusses the abstract “Analysis of Relief-of-Cough in Patients With Idiopathic Pulmonary Fibrosis Treated With Oral Nalbuphine Extended Release,” which aimed to assess the effectiveness of oral nalbuphine extended release in providing relief from chronic cough in patients with  IPF; the study used a clinical trial design to evaluate cough severity, with results showing that nalbuphine significantly reduced cough frequency and intensity, offering a potential new treatment option for managing this common and debilitating symptom of IPF.

Evaluating Cough Relief With Oral Nalbuphine in Patients With IPF

Steven Nathan, MD, discusses how the findings from the study on oral nalbuphine extended release suggest that this treatment may offer an effective option for managing IPF-related cough, providing significant relief in terms of both frequency and severity, which could shift current management strategies by introducing a more targeted, pharmacologic approach to addressing one of the most challenging symptoms of IPF.

Insights on Managing Cough Symptoms in Patients With IPF

Steven Nathan, MD, discusses how the study on inhaled treprostinil for CTD-PAH demonstrates its comparable efficacy to intravenous and subcutaneous forms, with a better safety profile, which could lead to improved patient adherence and management of CTD-PAH.

Key Insights on the Use of Inhaled Treprostinil in Treating CTD-PAH

Steven Nathan, MD, discusses additional noteworthy data from CHEST 2024 on emerging therapies for IPF and PAH and highlights his excitement for ongoing research focused on improving early detection, personalized treatments, and improving long-term patient outcomes.

Unmet Needs in IPF- and ILD-Related Pulmonary Hypertension and Emerging Therapy for IPF

The largest unmet needs in the treatment and management of idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) include the development of more effective therapies that can halt or reverse disease progression, as current treatments primarily focus on symptom management and slowing disease progression. Additionally, there is a need for improved diagnostic tools to enable earlier detection and intervention, as well as personalized treatment approaches that consider individual patient variability. Enhanced understanding of the underlying pathophysiological mechanisms is also crucial to inform the development of novel therapeutic targets.

Implications of IPF Survival Data for Clinical Practice and Early Intervention

EP: 1.CHEST 2024: Updates in IPF and PAH Care

EP: 2.Key Predictors of Survival in IPF: Findings From the IPF-PRO Registry

EP: 3.Implications of IPF Survival Data for Clinical Practice and Early Intervention

EP: 4.Evaluating Cough Relief With Oral Nalbuphine in Patients With IPF

EP: 5.Insights on Managing Cough Symptoms in Patients With IPF

EP: 6.Key Insights on the Use of Inhaled Treprostinil in Treating CTD-PAH

EP: 7.Unmet Needs in IPF- and ILD-Related Pulmonary Hypertension and Emerging Therapy for IPF